

David Barker, Former Illumina CSO, Joins GenVault's Scientific Advisory Board

CARLSBAD, Calif., September 28, 2007 – GenVault Corporation today announces that industry expert David Barker Ph.D. has joined its Scientific Advisory Board. In his role on the board, Dr. Barker will provide scientific guidance facilitating GenVault's entry into new biosample management markets. Dr. Barker brings more than 20 years experience in life science product commercialization as well as experience in serving on the boards of companies such as NextBio, Cell Biosciences, and Microchip Biotechnologies.

"Dr. Barker's extraordinarily deep understanding of the industry and its future will be extremely valuable as we chart our vision. We are very honored to welcome Dr. Barker as a key member of the GenVault advisory team," said David Wellis, CEO of GenVault

"Well-characterized biological samples and their intelligent storage and retrieval are essential for discovering disease genes and biomarkers. I am pleased to be asked to participate in GenVault's creative solutions for sample management " said Dr. Barker

Dr. Barker's previous product commercialization experience includes senior positions at Illumina as Vice President and Chief Scientific Officer; Amersham Biosciences as Vice President and Chief Science Advisor and Molecular Dynamics as Vice President of Research and Business Development until its acquisition by Amersham Biosciences. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

About GenVault

GenVault is redefining the global standard in biosample workflow and storage solutions for genomic medicine, discovery and identification. The company's room temperature technology reduces costs and empowers its partners to maximize their most valuable assets. As a scalable and reliable alternative to traditional freezers and DNA purification systems, GenVault's dry-state platform enables the extraction, preservation, recovery and distribution of DNA at room temperature. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. For more information visit us at www.genvault.com.